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Abstract
Background: Anxiety disorders are among the most prevalent psychiatric conditions, and are associated with poor
quality of life and substantial economic burden. Cognitive behavioural therapy is an effective treatment to reduce
anxiety symptoms, but is also costly and labour intensive. Cost-effectiveness could possibly be improved by delivering
cognitive behavioural therapy in a blended format, where face-to-face sessions are partially replaced by online sessions.
The aim of this trial is to determine the cost-effectiveness of blended cognitive behavioural therapy for adults with
anxiety disorders, i.e. panic disorder, social phobia or generalized anxiety disorder, in specialized mental health care
settings compared to face-to-face cognitive behavioural therapy. In this paper, we present the study protocol. It is
hypothesized that blended cognitive behavioural therapy for anxiety disorders is clinically as effective as face-to-face
cognitive behavioural therapy, but that intervention costs may be reduced. We thus hypothesize that blended
cognitive behavioural therapy is more cost-effective than face-to-face cognitive behavioural therapy.
Methods/design: In a randomised controlled equivalence trial 156 patients will be included (n = 78 in blended
cognitive behavioural therapy, n = 78 in face-to-face cognitive behavioural therapy) based on a power of 0.80,
calculated by using a formula to estimate the power of a cost-effectiveness analysis: n ¼ 2 zaþzβð Þ
2
sd2þ W2sd2ð Þ− 2Wρsdcsdqð Þð Þ
WE−Cð Þ2 .
Measurements will take place at baseline, midway treatment (7 weeks), immediately after treatment (15 weeks)
and 12-month follow-up. At baseline a diagnostic interview will be administered. Primary clinical outcomes
are changes in anxiety symptom severity as measured with the Beck Anxiety Inventory. An incremental cost-
effectiveness ratio will be calculated to obtain the costs per quality-adjusted life years (QALYs) measured by the
EQ-5D (5-level version). Health-economic outcomes will be explored from a societal and health care perspective.
Discussion: This trial will be one of the first to provide information on the cost-effectiveness of blended
cognitive behavioural therapy for anxiety disorders in routine specialized mental health care settings, both from
a societal and a health care perspective.
Trial registration: Netherlands Trial Register NTR4912. Registered 13 November 2014.
Keywords: Anxiety disorders, Panic disorders, Generalized anxiety disorder, Social phobia, Internet-based
treatment, Blended CBT, Cognitive behavioural therapy, Cost-effectiveness, Specialized mental health care,
Randomized controlled trial
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Background
Anxiety disorders are among the most prevalent psy-
chiatric disorders worldwide [1]. They are associated
with poor quality of life and a substantial economic
burden [2–4].
Estimates of annual health care costs associated with
anxiety disorders in the U.S. lie between $42 billion [5]
and $47 billion [6]. A measure of overall disease burden
is the disability-adjusted life year (DALY), expressed as
the number of years lost due to ill health, disability or
early death. The total global disease burden caused by
anxiety disorders was 390 DALYs per 100,000 persons in
2010, being the sixth leading cause of disability [7].
In the Netherlands, annual health care costs are es-
timated at €286 million. In 2007, anxiety disorders
accounted for 202,000 DALYs in the Netherlands, be-
ing third in the top ten list of medical disorders and
having a higher cost impact than depression, diabetes
mellitus or lung cancer [3].
Appropriate and efficient treatments are essential to
reduce the impact of severe anxiety disorders on public
health. These disorders can be treated effectively with
cognitive-behavioural therapies (CBT), whether or not
combined with pharmacotherapy. CBT is regarded as
one of the preferred treatments for anxiety disorders in
the Netherlands, set out in the multidisciplinary guide-
lines for anxiety [8] and international treatment guide-
lines [9, 10]. However, less than half of the patients with
anxiety disorders receive appropriate treatment [11], due
to anxiety-related avoidance behaviour, stigmatisation,
waiting lists, costs of therapy and distance from service
locations [12–14].
In recent years effort has been put in making less
expensive and easily accessible interventions available
for anxiety disorders while ensuring clinical effective-
ness. These include self-help interventions. Studies indi-
cate that these interventions did significantly better than
waiting lists in terms of reducing anxiety symptoms [15].
Another important strategy for lowering treatment costs
and improving accessibility are Internet interventions for
mental disorders such as depression, anxiety disorders
and problem drinking. Several meta-analyses have dem-
onstrated that anxiety treatment delivered via Internet
is more effective than non-intervening and that it can
be as effective as face-to-face treatment [14–22]. Reger
and Gahm [14], for example, showed that Internet- and
computer-based treatments for anxiety disorders were
superior to waitlist and that effects were equal to
therapist-delivered treatment. Cuijpers et al. [18] investi-
gated the effects of guided self-help on depression and
anxiety compared to face-to-face psychotherapies and
found no differences between the effects of both inter-
ventions. Andersson et al. [16] investigated the efficacy of
guided Internet-based CBT (iCBT) in direct comparison
to face-to-face CBT (fCBT) for psychiatric and somatic
disorders. They concluded that both treatments produce
equivalent effects.
Increasing emphasis is placed on cost-effectiveness of
health care programmes, because of pressure on health
care resources across the globe. In general, Internet
interventions may be more cost-effective than face-to-
face treatment. This has been confirmed in a recent
systematic review by Donker et al. [23], in which 16
studies with economic evaluations of Internet interven-
tions for anxiety, depression, smoking cessation and
alcohol consumption were included. Nordgren et al.
[24], for example, compared iCBT to an active waiting
list control condition and found it to be cost-effective
for primary-care patients with anxiety disorders with
an ICER of − $1824, indicating lower costs and larger
clinical effects in iCBT at post-test.
A rather new treatment approach combines face-to-
face treatment with Internet components into one inte-
grated treatment protocol [26]. This is called blended
treatment [25]. Using this approach, part of the face-to-
face treatment is replaced by Internet components, while
the traditional face-to-face relationship between ther-
apist and patient is retained. Blended treatment could
possibly lower the number of face-to-face contacts, in-
crease self-management competencies of patients and
thereby reduce the overall (direct) treatment costs. This
approach could also have a positive effect on waitlist
periods, as it is expected that therapists can take on more
patients, thereby reducing the number of patients that are
waitlisted [26]. Therefore, blended treatments appear an
attractive alternative for treatment as usual. However,
little is known about the clinical outcome and cost-
effectiveness of these treatments. In a recent study,
Volker et al. [27] investigated the effectiveness of a
blended intervention versus treatment as usual for sick-
listed employees with common mental disorders, such as
depression, anxiety and somatization disorders. Results
demonstrated that the group receiving the blended inter-
vention returned to work faster (27 days earlier on aver-
age) and had a greater chance of achieving remission than
the group receiving treatment as usual. As far as we know
there is no study yet investigating the cost-effectiveness of
blended treatment for anxiety disorders.
We therefore aimed to investigate the cost-effectiveness
of blended CBT (bCBT) for severe anxiety disorders. This
refers to the group of patients with an anxiety disorder
(panic disorder, social phobia or generalized anxiety dis-
order) who are referred to outpatient specialized mental
health care. Treating these patients in primary care set-
tings is not intensive enough given the severity of their
disorders, for example due to pervasive avoidance be-
haviour leading to functional disabilities, or because of
comorbidities that hamper treatment in primary care.
Romijn et al. BMC Psychiatry  (2015) 15:311 Page 2 of 10
We hypothesized that bCBT is equally as effective as
regular face- to-face CBT (fCBT), but that intervention
costs for blended CBT will be reduced.
Methods/design
Study design
The study is designed as a parallel-group randomized
controlled equivalence trial (N = 156), in which patients
with panic disorder, social phobia or generalized anxiety
disorder are randomly allocated to either bCBT (N = 78)
or fCBT (N = 78). The protocol for this study has been
approved by the Medical Ethics Committee of the VU
University Medical Centre, Amsterdam (registration num-
ber 2015.073). Written informed consent will be obtained
from all participants. Figure 1 displays the flowchart of
the study design, in accordance with the CONSORT
guidelines [28, 29].
Measurements
Measurements are taken at baseline (T0) and at three
fixed intervals after the first treatment session; at week
7 (T1), 15 (T2) and 67 (T3). Questionnaires are self-
administered online. The diagnostic interviews will be
administered by a trained researcher face-to-face at
the mental health care location. Appendix: Table 1
provides an overview of the measures that are used at
each time point.
Participants
Inclusion criteria
Patients aged 18 years and older are eligible to partici-
pate if they meet the criteria for a DSM-V diagnosis of a
severe anxiety disorder (social phobia, panic disorder with
or without agoraphobia and generalized anxiety disorder).
The Structured Clinical Interview for DSM disorders axis
I (SCID-I) [30] or the MINI international Neuropsychi-
atric Interview plus (MINI plus) [31, 32] will be performed
face-to-face by a trained researcher to assess these inclu-
sion criteria.
Exclusion criteria
Patients are excluded from the study if they i) do not
have adequate proficiency in the Dutch language, both
verbal and written, ii) do not have a valid e-mail address
and a computer with Internet access, iii) suffer from one
or more of the following disorders: a psychotic disorder,
bipolar disorder and/or substance dependence, iv) are
identified to be at high risk for suicide. The SCID-I [30] or
the MINI plus [31, 32] will be used to assess whether the
exclusion criteria iii) and iv) apply. Comorbid disorders
Fig. 1 Flowchart of the study design
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other than psychotic and bipolar disorders are allowed, as
is psychopharmacological treatment.
Excluded participants will be offered one of the regular
treatment options within the participating specialized
mental health care centre. For respondents with a height-
ened suicide risk, the principal investigator will inform
the professional responsible for treatment immediately
via telephone and e-mail.
Recruitment
Patients will be recruited at the anxiety disorder depart-
ments of three large scale specialized mental health care
centres in the Netherlands. All newly registered patients
undergo an intake interview by an experienced clinician,
after which diagnosis and treatment is established and
discussed with the patient.
Subsequently, eligible patients are informed about the
study by the researcher. Interested patients will then
receive an information brochure and an informed
consent form via e-mail and will be invited to take
the baseline diagnostic interview. During this interview, a
trained researcher will confirm the primary diagnosis of
panic disorder, social phobia or generalized anxiety dis-
order and assess comorbidity. If patients are willing and
eligible to participate, written informed consent will be
requested.
Randomization and blinding
Participants will be randomly assigned to either bCBT
or fCBT by an independent researcher, based on a
computer-generated block randomization table [28].
Randomization will be stratified by research site to
control for the differences between centres. Group allo-
cation cannot be blinded to patients and therapists
because they will obviously notice whether they perform
or receive bCBT or fCBT.
Interventions
Blended cognitive behavioural therapy
bCBT is a protocolized manualized treatment consisting
of 15 sessions, with weekly alternating 45-min face-to-
face sessions and online sessions (approximately 50-50 %)
with online feedback from the therapist. Online sessions
are accessible in a secure web-based environment (Mind-
district; www.minddistrict.com). Patients and therapists
access this platform with a personalized login. Performing
an online session will take patients approximately 45 min,
and providing online feedback will take therapists ap-
proximately 15 min per patient per session. Feedback
messages are sent on the online platform to ensure
secure communication.
The blended protocol is based on evidence-based
protocols for treatment of anxiety disorders and rec-
ommendations in national and international treatment
guidelines [8–10]. The protocol was developed in collab-
oration with patients, therapists and experts through
organized focus groups during the development phase of
the blended intervention, who provided feedback on the
content and presentation.
Key elements of bCBT are psycho-education (explan-
ation of the treatment rationale and the general proce-
dures in cognitive therapy), cognitive therapy (examining
relationships between thoughts, emotions and behaviour),
interoceptive exposure and exposure in vivo (exposure to
feared situations) and relapse prevention (identifying and
adopting strategies to prevent anxiety symptoms from re-
occuring). After a face-to-face introduction session with
an explanation of bCBT, the treatment starts with a face-
to-face session and it also ends with a face-to-face session.
The online sessions have a fixed structure that starts
with therapy information, followed by multiple exercises
and homework assignments. The sessions contain text
boxes with information and testimonials from fictional
patients and videos in which a therapist explains the
theory. Patients get online feedback from their therapist
on finished exercises at a fixed day and time. Homework
assignments are discussed in the subsequent face-to-face
session.
On completion of treatment, patients can continue to
access the online treatment platform in order to reread
information and look up homework exercises, such as
the relapse prevention plan.
Face-to-face cognitive behavioural therapy
The fCBT entails fifteen weekly 45-min face-to-face ses-
sions with psycho-education, cognitive therapy, interocep-
tive exposure, exposure in vivo and relapse prevention.
Therapists follow a protocol with the same content as the
bCBT protocol.
Therapists
All participating therapists are experienced clinicians
and will be trained in the bCBT protocol and the fCBT
protocol prior to the study. During the training they are
informed about the content and the structure of the
protocol and they receive instructions about how to
work with the online platform. Therapists work with
both treatment groups. During the trial, therapists will
attend peer group supervision meetings every other
week. The supervision meetings are guided by the head
researcher at the centre (an experienced psychologist)
and the research coordinator.
Clinical outcome measures
Severity of anxiety symptoms
The Beck Anxiety Inventory (BAI) [33] will be used to
measure the severity of anxiety symptoms at every
assessment moment (T0-T3). The BAI is a reliable and
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well-validated measure of somatic anxiety symptoms
found across the anxiety disorders [34]. It consists of
twenty-one questions about how the subject has been
feeling in the last week, expressed as common symptoms
of anxiety (such as numbness and tingling, sweating not
due to heat, and fear of the worst happening). Each
question has the same set of four possible answer op-
tions, which are arranged in columns and are answered
by marking the appropriate one with an X. The BAI has
a maximum score of 63. For this study, treatment re-
sponse is defined as a symptom reduction of the baseline
BAI symptom severity score of at least 30 % and remis-
sion a score reduction of at least 30 % plus a total score
<11, based on validation in The Netherlands Study of
Depression and Anxiety (NESDA) [35–37].
Measures of quality adjusted life years
General well-being
The EQ-5D-5L [38, 39] will be administered at all time
points (T0-T3) to assess health related quality of life.
This validated questionnaire consists of five questions
that tap mobility, self-care, daily activities, pain and
mood. Each item has five response categories. The labels
for each of the dimensions are: no problems, slight prob-
lems, moderate problems, severe problems and incap-
acity/extreme problems. In addition to this, participants
use a VAS scale to rate their health on a scale ranging
from 0 (worst possible health) to 100 (best possible
health). The answers to the five questions are combined
in a number sequence that corresponds with the five
answers. Each sequence corresponds to a certain health
state. On these health states, a value (utility) has been
placed [40], which in turn is used to determine the
quality-adjusted life years (QALYs). To obtain a utility
score per patient, the area-under-the curve method
(AUC) will be applied [41]. This method consists of
linearly interpolating between the different health states
at the different time points. Subsequently, the area under
the curve is calculated.
Cost calculations
The cost-effectiveness will be assessed taking a societal
and health care perspective. Cost within health care, costs
to the patient and productivity costs are taken into ac-
count. The Treatment Inventory of Costs in Psychiatric
patients (TiC-P) will be applied to collect input data on
costs. The TiC-P is a validated comprehensive question-
naire focused on establishing costs incurred within and
outside the health care system as well as costs due to
productivity losses [42].
Health care utilization costs and patient costs
Part 1 of the TiC-P is a validated instrument that mea-
sures the direct medical costs by calculating the number
of contacts with health care services (general practi-
tioner, psychiatrist, medical specialist, physiotherapist,
alternative health practitioner, day care/hospital length
of stay), during the last three months. Also, information
about the number of contacts and time spent by the
patient on the online part of the intervention will be
collected. Additionally, patients’ out-of-pocket costs,
such as the costs of travelling to the health services and
the patients’ time costs of travelling are determined.
Apart from these costs, the costs of offering the treat-
ments will be taken into account. For example the costs
of developing and maintaining the online part of the
treatment, as well as the costs of weekly therapist online
feedback. The costs are calculated by multiplying the
volumes by the corresponding reference unit prices [43].
Productivity costs
The second part of the TiC-P contains the iPCQ. This
part asks questions about productivity losses that are
caused by absence (absenteeism), reduced efficiency at
work (presenteeism) and difficulties in job performance.
Sickness absence for less than one month is defined as
short-term absence, and sickness absence for more than
one month as long-term absence. If respondents indi-
cated that they had been absent for the entire recall
period, data were collected from the time when the
period of long-term absence started. This additional
information will be used to value the production losses
according to the friction cost method [44]. This method
takes into account the economic circumstances that
limit the losses of productivity to society, which are
related to the fact that a formerly unemployed person
may replace a person who becomes disabled. Productiv-
ity losses were valued according to the average value
added per worker by age and gender per day and per
hour prices [43].
Other variables of interest
To further evaluate bCBT compared to fCBT, a number
of explorative measures are administered.
General patient characteristics and treatment preference
Demographic characteristics such as age, sex, educa-
tion, employment and marital status will be collected
with a general demographic questionnaire at baseline
(T0). Additional questions are asked concerning clin-
ical anxiety characteristics such as age of onset, num-
ber of months with an anxiety disorder in past 4 years,
duration of current episode, somatic illnesses and treat-
ment status. In addition, participants are asked about their
computer use: number of hours spent at a computer and
reasons for use. Finally, patients indicate their treatment
preference (bCBT/fCBT).
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Depression
The Beck Depression Inventory-II (BDI-II) [45] is a
21-question multiple choice self-report inventory of
the most widely used instruments for measuring the
severity of depression and assesses the presence and
severity of depressive symptoms. The BSI-II has been
validated in Dutch [46]. It will be used at every time
point (T0-T3).
Work and social adjustment
The Work and Social Adjustment Scale (WSAS) [47] is
a 5-item patient self-report measure, which assesses
the impact of a person’s mental health difficulties on
their ability to function in terms of work, home man-
agement, social leisure, private leisure and personal or
family relationships at all time points (T0-T3). The
WSAS is used for all patients with depression or anx-
iety as well as phobic disorders. It is a reliable and
valid measure [47].
General psychopathology
The Brief Symptom Inventory (BSI) [48] is a 53-item,
self-report symptom inventory designed to evaluate
general psychopathology at every time point (T0-T3).
It is a brief form of the SCL-90 and is designed to
provide a multidimensional symptom measurement in
about 10 min. The questionnaire has been validated
in Dutch [49].
Locus of control
The five-item version of The Mastery Scale [50] is
administered at each assessment moment (T0-T3) to
assess changes in locus of control. Locus of control could
potentially mediate treatment effect and facilitate relapse
prevention. The questionnaire consists of five questions,
which are scored on a five-point Likert-scale, ranging
from 1 (totally disagree) to 5 (totally agree). The total
score ranges from 5 to 30, with higher scores being indi-
cative of a higher level of experienced control. The scale
has good psychometric properties [50].
Therapeutic alliance
The Revised Short Version of the Work Alliance Inven-
tory (WAI-SR) [51, 52] is used to let patients rate the
quality of the work alliance between patient and therap-
ist at T1 (week 10). The questionnaire is administered to
investigate whether the blended treatment has an effect
on the quality of the work alliance.
The questionnaire consists of 12 items, which are
scored on a five-point Likert-scale, ranging from 1 (sel-
dom or never) to 5 (always). The raw scores range from
12 to 60, with higher scores being indicative of a better
alliance between therapist and patient. The question-
naire has satisfactory psychometric properties [51].
Treatment evaluation
The Client Satisfaction Questionnaire-8 (CSQ-8) [53]
will be administered at week 15 (T2). The CSQ consists
of 8 questions with item-specific response categories.
The total score ranges from 8 to 32, with higher scores
being indicative of higher levels of client satisfaction.
The CSQ-8 has a high internal consistency [54].
The System Usability Scale (SUS) [55] will be ad-
ministered at week 15 (T2) amongst the participants
randomized to the bCBT group. The SUS consists of
10 questions with 5 response options, ranging from 0
(strongly disagree) to 4 (strongly agree). The total scores
are converted to a scale ranging from 0 to 100. Higher
scores are indicative of higher usability of the online plat-
form that is used for bCBT. It has been found to be a
reliable questionnaire [56].
Process data
Data for process analyses are obtained from the adminis-
tration of the participating mental health care institu-
tions and through usage statistics of the online platform.
We will consider the following aspects:
– Recruitment: time required for the recruitment of
patients
– Treatment adherence: percentage of dropout during
therapy, number of completed sessions, reasons for
treatment dropout, number of face-to-face contacts
and number of cancellations, homework adherence
– Time investment: by both the patient and the
therapist
Sample size
In economic evaluations we are calculating the power
to estimate the joint distribution of costs and treat-
ment effects. Subsequently, we need more information
for estimating power compared to clinical trials, namely
expected costs of treatments, expected covariance of treat-
ment effects/costs, and the maximum willingness to pay
for the treatment effect. To incorporate this information,
the formula of Glick et al. [57] can be used. A goal of
sample size and power calculation for cost-effectiveness
analysis is to identify the likelihood that an experiment
will allow us to be confident that a therapy is acceptable
or not when we adopt a particular willingness to pay.
For this study a sample size of 156 is based on a formula
to estimate the power of a cost-effectiveness analyses.
n ¼ 2 za þ zβ
 2
sd2 þ W 2sd2 − 2Wρsdcsdq
  
WE−Cð Þ2
Where:
N = sample size/group
zα = z statistic for alpha
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zβ = z statistic for beta
sdc = Expected standard deviation costs
sde = Expected standard deviation effects
W = Willingness to pay
C = Expected differences in costs
E = Expected differences in effects
ρ = correlation between differences in costs and effects
(zα = 1,96; zβ = 0,84; sdc = 800; sde = 0,02; W = 80,000;
C = 832; E = 0,02; ρ = 0,1)
Based on the literature of the similar effectiveness of
iCBT compared to fCBT, we will conduct an equivalence
study to show that bCBT and fCBT do not differ signifi-
cantly in their short- and long-term effectiveness (ex-
pected between-groups effect-size d of 0.2). The sample
size in this equivalence study is based on an applied
equivalence limit difference ES of 0.4, as this range of
small to moderate difference in effect size will not result
in clinically important differences. The power of this
study that both treatments are similar is set at 0.80
with an alpha of 0.05 to calculate sample size and re-
sulted in the inclusion of 78 patients per condition
(total n = 156). This was supported by the estimates
based on the formula.
Statistical analysis
Primary analysis
A cost-effectiveness analysis (CEA) will be conducted
from the societal perspective. In addition, a budget im-
pact analysis (BIA) will be based on a health-economic
modelling study in accordance with Mauskopf ’s recom-
mendations [58], i.e. from the perspective of the health
care decision maker.
Cost-effectiveness analysis
Costs will be assessed at pre-, post-treatment and at
one-year follow up. As the TIC-P cost date covers a
period of three months, all costs will be extrapolated to
a 12 month period, assuming stability of costs during
the time frame. A multilevel model (to correct for
correlation between measurements) with a link function
(as cost-data will not be normally distributed) is used to
obtain parameter estimates, likelihood and p-values for
the costs and effects. The fitted estimates will be boot-
strapped to assess confidence intervals [59]. An incre-
mental cost-effectiveness ratio (costs per case response
or remission) will be calculated (ICER = (mean costs
bCBT treatment-mean costs fCBT)/(mean bCBT − mean
fCBT). The mean costs, including all costs, of the patients
in the bCBT condition will be subtracted from the mean
costs of the patients in the fCBT condition. This difference
will then be divided by the subtracted effects (case of
response or remission on the BAI) and an estimation of
the bCBT treatment groups’ incremental costs in relation
to their incremental health benefit will be generated.
Additionally, an incremental cost-utility ratio (costs per
QALY) will be calculated; this procedure is identical to
the cost-effectiveness ratio with the exception that instead
of the cost per QALY, the cost per case of response or
remission, is calculated. Finally, to test the robustness of
the results, we will conduct sensitivity analyses, to investi-
gate how sensitive the ICERs will be to changes of cost
estimates (for example difference in costs per bCBT con-
tact, type of psychologists and number of sessions). For
decision-making purposes, the ICER acceptability curve
will be plotted for various willingness-to-pay (WTP)
ceilings, which helps in making judgments about whether
the blended intervention offers good value for money,
relative to treatment as usual. One-way sensitivity analyses
directed at uncertainty in the main cost drivers will be
performed to gauge the robustness of our findings across
a range of likely values for those parameters.
Budget impact analysis
To assess how health care budgets are changed by offer-
ing bCBT for anxiety compared to fCBT, a budget
impact analysis (BIA) will be conducted as outlined in
Mauskopf et al. [58]. The BIA will include 1) the
perspective of the public purse (in Dutch: Budgettair
Kader Zorg), and 2) the perspective of the health care
decision makers. We consider costs when 10, 20, 30 and
100 % of the target group receive bCBT compared to
fCBT. These scenarios will be compared with the base-
case scenario, reflecting current care, where 0 % of the
target group is offered blended CBT. The BIA will be
conducted taking account of the perspectives of health
care decision makers. For this, the average remuneration
rates of the Dutch Health Authority will be used (NZa).
The Budget Impact Analysis (BIA) will be conducted
using a health economic (Markov cohort) simulation
model.
Explorative analyses
Outcomes on continuous clinical outcome variables,
such anxiety symptoms, at T1, T2 and T3 (week 7, 15,
and 67) are estimated for descriptive purposes through
mixed-model analyses (MM), with participants as random
effects, and time (T1-T3), group (blended vs. face-to-face
treatment) and time x group as fixed effects, with baseline
scores as a single covariate. Missing data will be imputed
statistically. To assess the magnitude of treatment effects,
Cohen’s d effect sizes [60] for each time point are calcu-
lated by dividing MM parameter estimates of fixed effects
at each post-treatment assessment by the pooled standard
deviation of outcome measurements at baseline (T0).
Discussion
The study described is a randomized controlled trial in
which the health care efficiency of bCBT for adults with
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panic disorder, social phobia or generalized anxiety
disorder in outpatient specialized mental health care
is examined. The main goal is to assess the cost-
effectiveness of bCBT in comparison to fCBT, from a
societal and a health care perspective.
Both national and international studies have shown
that the costs of anxiety disorders are substantial. This is
reflected in health care costs and loss of productivity.
bCBT has the potential to increase the cost-effectiveness
compared to fCBT, mainly due to its effectiveness com-
bined with less therapist time needed and fewer patients’
visits to therapist. bCBT may also increase patients’ self-
management; they have more control over time and
frequency of treatment, because they can access the online
platform as often and as long they want, in combination
with therapist support. The fact that blended CBT may
benefit patients and therapists and can be executed quite
easily and possibly at less cost than conventional CBT,
means that it is potentially very interesting for health care
institutions to be able to deliver this type of treatment,
and for health care insurance companies to include these
treatments in their reimbursement programs.
However, clinical and economical evaluations of this
type of treatment are still scarce. Several studies confirm
the effectiveness and cost-effectiveness of iCBT for de-
pression and anxiety disorders [23], but none of these
studies investigated cost-effectiveness of blended CBT
for anxiety disorders in specialized mental health care.
By adopting a societal perspective in this study all rele-
vant information that may be of interest for the
decision-making process is incorporated in the analysis.
Hence, in this study, patients’ time and productivity
costs are part of the assessment.
A strong feature of the current trial is that therapy
content of fCBT and bCBT is similar, captured in a
protocol for both conditions. Both interventions entail
clinical behavioural therapy and exposure, a daily routine
treatment for anxiety disorders. In addition, the recruit-
ment of patients and inclusion and exclusion criteria are
similar to the usual procedures in mental health organi-
zations, which enhances the external validity of the
results that will be obtained.
The strength of high external validity is simultan-
eously a limitation with regard to internal validity.
The study is designed to closely adhere to established
procedures in routine practice in outpatient special-
ized mental health care, which can make it difficult
to attribute clinical results to the blended treatment.
However, with this study we want to gain insight into
the cost-effectiveness of bCBT, rather than its clinical
effectiveness.
Furthermore, we aim to collect follow-up data after a
year. Therefore, an inherent challenge to the study is re-
tention. To minimize drop-out, reminders for filling in
questionnaires will be sent by e-mail and if deemed
necessary, participants will be called personally to re-
mind them and possibly fill in the questionnaire together
during the phone call. To handle missing data, we will
impute missing values statistically.
Appendix
Table 1 Overview of measures administered at each assessment interval
Questionnaire Aim Baseline (T0) Week 7 (T1) Week 15 (T2) Week 67 (T3)
Primary outcomes
BAI Anxiety severity x x x x
SCID-I/MINI-plus Diagnostic interview x
EQ-5D-5L General well-being x x x x
TiC-P Health-care utilization x x x
Other variables of interest
General patient characteristics x
A priori treatment preference x
BDI Depression x x x x
WSAS Work and social adjustment x x x x
BSI General psychopathology x x x x
CSQ Satisfaction x
Mastery Scale Locus of control x x x x
WAI Therapeutic alliance x
SUS (bCBT only) System usability x
BAI Beck Anxiety Inventory, SCID Structured Clinical Interview for DMS disorders axis I, MINI plus Mini International Neuropsychiatric Interview Plus, EQ-5D-5L EuroQol,
iC-P Trimbos and iMTA questionnaire on Costs associated with Psychiatric illness, BDI Beck Depression Inventory, WSAS Work and Social Adjustment Scale, BSI Brief
Symptom Inventory, CSQ Client Satisfaction Questionnaire, WAI Work Alliance Inventory, SUS System Usability Scale, bCBT blended Cognitive Behavioural Therapy
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